Holen Sie sich die Stockscreener-App
27.22
2.76%
0.73
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.49
Offen:
$26.67
24-Stunden-Volumen:
50.28M
Relative Volume:
0.81
Marktkapitalisierung:
$154.76B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
20.09
EPS:
1.3551
Netto-Cashflow:
$10.38B
1W Leistung:
+2.95%
1M Leistung:
+7.04%
6M Leistung:
+13.75%
1J Leistung:
+5.38%
1-Tages-Spanne:
$26.52
$27.37
1-Wochen-Bereich:
$25.26
$27.37
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.22 | 150.61B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,058.18 | 913.67B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.99 | 572.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.43 | 387.09B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
MRK
Merck Co Inc
|
121.93 | 297.22B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
AZN
Astrazeneca Plc
|
193.03 | 290.15B | 58.07B | 9.40B | 9.87B | 3.0115 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer CEO discusses the company's GLP-1 weigh-loss drug pipeline - Yahoo Finance UK
Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus - TechStock²
What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders - Yahoo Finance
3 Healthcare Stocks Paying the Highest Dividends of 2026 - The Motley Fool
Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus - TechStock²
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push - The Globe and Mail
GoodRx (GDRX) Partners with Pfizer for Discounts on TrumpRx - GuruFocus
Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults: What Investors Should Know - TipRanks
GoodRx becomes pricing source for Pfizer and other drugmakers on TrumpRx - Seeking Alpha
This Week’s Leadership Moves: Delta Air Lines, Pfizer, NASA - CDO Magazine
FDA Grants Priority Review for Pfizer’s HYMPAVZI - Contract Pharma
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst - TechStock²
Pfizer wins FDA priority review for Hympavzi label expansion - Seeking Alpha
Pfizer Receives US FDA Priority Review for Expanded Hemophilia Treatment Use - marketscreener.com
Pfizer seeks FDA approval for hemophilia drug in younger patients - Investing.com
Macrolide Antibiotics Market to Get an Explosive Growth| Pfizer Inc., Merck & Co., Inc. - openPR.com
Pharmaceutical Market Poised for Transformation Inspired - openPR.com
Pfizer launches TrumpRx program offering up to 85% discount on medicines - Investing.com
Contraceptive Pills Market Is Going to Boom | Pfizer Inc • Bayer AG • Organon & Co - openPR.com
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans - BioSpace
Is Pfizer (PFE) Pricing Reflect Its Prospects After Reshaping Portfolio And Covid Outlook? - Yahoo Finance
Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans - marketscreener.com
Pfizer pops on Q4 results but this may be the catalyst that matters most - MSN
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most - MarketBeat
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook - TechStock²
March 27th Options Now Available For Pfizer (PFE) - Nasdaq
Big Pharma CEOs set sights on massive growth in years to come - Pharma Voice
Pfizer Stock Forecast: Trending Outlook From Street Watchers - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Pfizer Announces 2025 Grant Recipients Driving Innovative Solutions in Cancer Care - BioSpace
Aamir Malik: Our New Campaign Focuses on Helping People With Their First Steps in Screening - Oncodaily
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? - The Globe and Mail
Pfizer’s Obesity Bet PF-3944 Advances As Shares Screen Undervalued - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail
Pfizer Inc. (PFE): A Bull Case Theory - Insider Monkey
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop - TechStock²
Pfizer’s experimental weight loss drug shows promise in mid-stage trial - AOL.com
Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss - Finviz
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus - TechStock²
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive
Pfizer Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:PFE) 2026-02-04 - Seeking Alpha
Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript - Insider Monkey
Pfizer Announces 2025 Grant Recipients Driving Innovative Solutions in Cancer Care (2026-02-04) - Seeking Alpha
Novo Nordisk: Pfizer weight loss drug offers credible new competition - Yahoo Finance
PFIZER INC : Gets a Neutral rating from Goldman Sachs - marketscreener.com
Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative - Morningstar Canada
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs - BioSpace
Skipping the Super Bowl, Pfizer unveils new cancer campaign that still nods to sportsMM+M - Medical Marketing and Media
Pfizer channels Al Pacino’s ‘Any Given Sunday’ speech in fight against cancer - Ad Age
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):